Core Insights - Baxter International Inc. is currently among the Top 15 Lowest P/E Ratios of the S&P 500 for 2025, indicating a potentially undervalued stock [1] - Analysts have a consensus Hold recommendation for Baxter, with a one-year average share price target of $23.80, suggesting an upside potential of 28% [4] Financial Adjustments - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter from $19 to $15 while maintaining an Underweight rating [1] - Argus Research downgraded Baxter on October 31, citing a significant dividend reduction expected to drive an annual cash flow boost of $300 million or more, aimed at strengthening the balance sheet [3] Market Position and Performance - The company is well-positioned in the medical technology sector due to favorable trends in hospital spending and key product launches [2] - Baxter's stock has faced challenges, declining 36% year to date [4] - Concerns have been raised regarding the weak outlook for Baxter's IV fluid solutions business [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [4][5]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions and risks to patient safety [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [6]. Group 2: Financial Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries related to the Novum LVP but failed to take adequate remedial measures [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm encourages anyone with information regarding Baxter's conduct to come forward, including whistleblowers and former employees [7].

NEW YORK, Dec. 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk. ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, ...

Core Insights - The SCCM Enhanced Equity Income Fund reported a composite return of 0.9% in Q3 2025, underperforming compared to the S&P 500 Buy-Write Index which returned 3.5% [1] - Baxter International Inc. (NYSE:BAX) was highlighted as a significant stock, with a one-month return of 2.67% and a 52-week gain of 41.89% [2] - The fund exited its position in Baxter due to ongoing challenges, including a 40% dividend cut and operational issues, despite recognizing its long-term recovery potential [3] Fund Performance - The S&P 500 returned 8.1% in Q3 2025, while the Russell 1000 Value increased by 5.3% [1] - The fund's performance was notably lower than the S&P 500 Buy-Write Index, which returned 3.5% [1] Baxter International Inc. Analysis - Baxter's stock closed at $18.48 on December 4, 2025, with a market capitalization of $9.5 billion [2] - The company faced significant challenges post-COVID, including margin pressure and pricing issues from hospital Group Purchasing Organizations [3] - Management's decision to cut the dividend by 40% and change the CEO indicates ongoing financial struggles [3] Hedge Fund Interest - Baxter International Inc. was held by 38 hedge fund portfolios at the end of Q3 2025, an increase from 31 in the previous quarter [4] - Despite its potential, analysts suggest that certain AI stocks may offer better investment opportunities with less risk [4]

NEW YORK  , Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX).Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=179558&from=4CLASS PERIOD: F ...

Core Viewpoint - Baxter International Inc. has announced early tender results for cash tender offers for its 2026 and 2027 Notes, with a maximum purchase price of up to $600 million for the 2027 Notes [1][2]. Group 1: Tender Offer Details - The tender offers include the purchase of all 2.600% senior unsecured notes due 2026 and a portion of the 1.915% senior unsecured notes due 2027 [2]. - The total principal amount of the 2026 Notes outstanding is $750 million, with $420.589 million tendered by the early tender date [4]. - For the 2027 Notes, the total outstanding is $1.45 billion, with $1.08866 billion tendered [4]. Group 2: Early Tender Date and Settlement - The early tender date was set for December 3, 2025, at 5:00 p.m. New York City time, after which withdrawal rights expired [3]. - The company plans to make payments for the validly tendered notes on December 8, 2025, which is the early settlement date [4]. Group 3: Total Consideration and Pricing - The total consideration for the notes accepted for purchase will include an early tender payment of $30.00 per $1,000 principal amount and will be determined based on the applicable fixed spread and yield of U.S. Treasury reference securities [5]. - The total consideration will be announced on December 4, 2025, at 10:00 a.m. New York City time [5]. Group 4: Pro Rata Acceptance - Due to the expected exceedance of the maximum tender cap for the 2027 Notes, any tendered 2027 Notes will be accepted on a pro rata basis [6]. - The company does not anticipate accepting any 2027 Notes tendered after the early tender date [6]. Group 5: Conditions and Management - The tender offers are subject to certain conditions, including the financing condition specified in the Offer to Purchase [8]. - Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC are the dealer managers for the tender offers [9].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. and certain executives for alleged violations of federal securities laws [1] Summary by Relevant Sections - **Company Overview** - Baxter International, Inc. is facing legal action from Bernstein Litowitz Berger & Grossmann LLP, a law firm specializing in investor rights [1] - **Legal Action Details** - The lawsuit was filed in the U.S. District Court for the Northern District of Illinois [1] - The action is on behalf of all investors who purchased or otherwise acquired shares of Baxter [1]